Immune Network Ltd. (IMMFF), announces the completion of a Phase II trial of a once-daily M. vaccae pill (V7) conducted by Immunitor in Ukraine. The imm02 study was aimed to seek whether oral formulation of inactivated whole cell mycobacteria can shorten TB treatment duration.

Immune Network Ltd. (IMMFF:PK), announces that Immunitor presented one month trial results in 106 patients with tuberculosis who were given daily pill of oral Mycobacterium vaccae therapeutic vaccine (V7). The data were summarized in a poster at “Drug Resistance and Persistence in Tuberculosis” of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation and sponsored by GlaxoSmithKline. The meeting took place on May 13-18, 2012 at Speke Resort & Conference Centre, Kampala, Uganda.